Hepatitis B vaccine recombinant SBAS4 - GlaxoSmithKline

Drug Profile

Hepatitis B vaccine recombinant SBAS4 - GlaxoSmithKline

Alternative Names: Fendrix; HBs AG/AS04; SB M00026; SBAS4

Latest Information Update: 04 Aug 2005

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Hepatitis B vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Hepatitis B

Most Recent Events

  • 12 Jul 2005 Corixa Corporation acquired by GlaxoSmithKline
  • 27 Oct 2004 The Committee For Medicinal Products for Human Use (CHMP) recommends approval of the vaccine for hepatitis B prevention in the European Union
  • 12 May 2003 Preregistration for Hepatitis B prevention in European Union (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top